Gyre Therapeutics (GYRE) Capital Expenditures (QoQ) (2010 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Gyre Therapeutics | 532.38 Mn | 518.25 Mn | 8.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 23.61% |
| Dec 31, 2025 | -78.44% |
| Sep 30, 2025 | 160.94% |
| Jun 30, 2025 | 109.84% |
| Mar 31, 2025 | 287.69% |
| Dec 31, 2024 | -109.38% |
| Sep 30, 2024 | -52.40% |
| Jun 30, 2024 | 530.30% |
| Mar 31, 2024 | -90.06% |
| Dec 31, 2023 | 17.73% |
| Sep 30, 2023 | -20.31% |
| Jun 30, 2023 | 42.19% |
| Sep 30, 2020 | 1,118.75% |
| Jun 30, 2020 | -5.88% |
| Mar 31, 2020 | 1,800.00% |
| Dec 31, 2019 | -200.00% |
| Sep 30, 2019 | -97.96% |
| Jun 30, 2019 | 226.67% |
| Mar 31, 2019 | -91.43% |
| Jun 30, 2018 | -98.48% |
| Mar 31, 2018 | 890.00% |
| Mar 31, 2017 | -97.54% |
| Dec 31, 2016 | 454.55% |
| Sep 30, 2016 | -90.64% |
| Jun 30, 2016 | 164.04% |
| Mar 31, 2016 | -9.18% |
| Jun 30, 2013 | -68.57% |
| Mar 31, 2013 | -64.10% |
| Dec 31, 2012 | 19,400.00% |
| Sep 30, 2012 | -98.90% |
| Jun 30, 2012 | 97.83% |
| Mar 31, 2012 | -81.75% |
| Dec 31, 2011 | 50.90% |
| Sep 30, 2011 | -59.66% |
| Jun 30, 2011 | -30.77% |
| Mar 31, 2011 | -62.88% |
| Dec 31, 2010 | 717.77% |